Literature DB >> 3143572

Mechanisms of beta-lactam resistance in Haemophilus influenzae.

L Gutmann1, R Williamson, E Collatz, J F Acar.   

Abstract

Haemophilus influenzae has become increasingly resistant to beta-lactam antibiotics. Three major mechanisms, both enzymatic and non-enzymatic, are involved. Enzymatic resistance is mainly due to production of a TEM-1 plasmid-mediated beta-lactamase, and in some cases to a new enzyme ROB-1. Of the non-enzymatic mechanisms, decreased permeability due to alteration of outer membrane proteins seems to be rare in comparison to decreased affinity of penicillin-binding proteins for beta-lactam antibiotics. Enzymatic resistance is present in about 10-20% of clinical isolates, while non-enzymatic resistance is present only in 2-4%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143572     DOI: 10.1007/bf01964237

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  43 in total

Review 1.  Molecular basis of bacterial outer membrane permeability.

Authors:  H Nikaido; M Vaara
Journal:  Microbiol Rev       Date:  1985-03

2.  A major outer-membrane protein functions as a porin in Haemophilus influenzae.

Authors:  J L Burns; A L Smith
Journal:  J Gen Microbiol       Date:  1987-05

3.  [A new mechanism of resistance to ampicillin by production of beta-lactamase ROB-1 in a strain of Haemophilus influenzae isolated in France].

Authors:  B Joly; C Delmas; C Rich; M F Prere; V Livrelli; H Dabernat
Journal:  Presse Med       Date:  1987-05-16       Impact factor: 1.228

4.  [Drug sensitivity of Haemophilus sp. and transfer of resistance into E. coli (author's transl)].

Authors:  F W Goldstein; A Boisivon; P Leclerc; J F Acar
Journal:  Pathol Biol (Paris)       Date:  1977-05

5.  Letter: Penicillinase production by Haemophilus influenzae.

Authors:  J D Williams; S Kattan; P Cavanagh
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

Review 6.  The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria.

Authors:  A Tomasz
Journal:  Annu Rev Microbiol       Date:  1979       Impact factor: 15.500

7.  Molecular epidemiology of plasmid-mediated ampicillin resistance in Haemophilus influenzae type b isolates from Alaska.

Authors:  P M Mendelman; V P Syriopoulou; S L Gandy; J I Ward; A L Smith
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

8.  Effect of inoculum size on the susceptibility of Haemophilus influenzae b to beta-lactam antibiotics.

Authors:  V P Syriopoulou; D W Scheifele; C M Sack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

9.  The permeability barrier of Haemophilus influenzae type b against beta-lactam antibiotics.

Authors:  J W Coulton; P Mason; D Dorrance
Journal:  J Antimicrob Chemother       Date:  1983-11       Impact factor: 5.790

10.  Comparative activity of mezlocillin, penicillin, ampicillin, carbenicillin, and ticarcillin against gram-positive bacteria and Haemophilus influenzae.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

View more
  3 in total

1.  Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Study Group.

Authors:  L D Tremblay; J L'Ecuyer; P Provencher; M G Bergeron
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

2.  Amoxicillin treatment of experimental acute otitis media caused by Haemophilus influenzae with non-beta-lactamase-mediated resistance to beta-lactams: aspects of virulence and treatment.

Authors:  A Melhus; H Janson; E Westman; A Hermansson; A Forsgren; K Prellner
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Molecular epidemiology of ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae.

Authors:  L Gazagne; C Delmas; E Bingen; H Dabernat
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.